+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

US Diagnostic Biomarker Market 2019-2025

  • PDF Icon


  • January 2020
  • Region: United States
  • Orion Market Research Private Limited
  • ID: 4988048
UP TO OFF until Dec 31st 2022
US Diagnostic Biomarker Market Size, Share & Trends Analysis Report by Diagnostic Technique (ELISA, Colorimetric Assay, Liquid Chromatography-Mass Spectrometry, Particle-Enhanced Turbidimetric Immunoassay, and Others), By Application (Oncology, Cardiology, Neurology, Nephrology, and Others), and Forecast 2019-2025.

The US diagnostic biomarker market is estimated to grow significantly at a CAGR of more than 12% during the forecast period. Factors that are contributing significantly in the market growth include the presence of well-developed healthcare infrastructure, increasing healthcare R&D investments, high healthcare expenditure and others. Moreover, the market growth is attributed to the rising prevalence of cancer, CVDs, and chronic diseases. The rising number of cancer patients is considered to be one of the major factors that are driving the growth of the market in the US.

The US diagnostic biomarker market is segmented on the basis of diagnostic technique and application. On the basis of the diagnostic technique, the market is segmented into ELISA, colorimetric assay, liquid chromatography-mass spectrometry, particle-enhanced turbidimetric immunoassay and other. Further, on the basis of application, the market is segmented into oncology, cardiology, neurology, nephrology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. A large number of research is going on finding a diagnostic biomarker for various types of cancer so that early detection can be done.

The major players in the North American diagnostic biomarker market include Abbott Laboratories, Inc., Thermo Fisher Scientific, inc., Becton Dickinson and Co., Pfizer Inc., Quest Diagnostic Inc., and others. These companies are launching innovative products in the market, in order to meet the increasing demand for an effective diagnostic biomarker for cancer and cardiovascular diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the competitive market, which includes partnership and collaboration, and investments. For instance, Astute Inc. in March 2017, entered into two agreements to expand global access to the NephroCheck Test. The company expanded its agreement with Ortho Clinical Diagnostics to add more countries under a new European distribution deal. In addition, the company established a distribution agreement with bioMérieux in the US for promoting the NephroCheck Test of Astute Medical on Astute140 Meter in the US.

Research Methodology

The market study of the US diagnostic biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for healthcare companies, research institutes, hospitals, pharmaceutical, and biotechnology companies, potential investors and venture capitalists, government organizations, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis of the market size and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. US Diagnostic Biomarker Market Research and Analysis by Diagnostic Technique
2. US Diagnostic Biomarker Market Research and Analysis by Application

The Report Covers
  • Comprehensive research methodology of the US Diagnostic Biomarker Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the US Diagnostic Biomarker Market.
  • Insights about market determinants which are stimulating the US Diagnostic Biomarker Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. US Diagnostic Biomarker Market by Diagnostic Technique
5.1.1. ELISA
5.1.2. Colorimetric Assay
5.1.3. Liquid Chromatography-Mass Spectrometry
5.1.4. Particle-Enhanced Turbidimetric Immunoassay
5.1.5. Others
5.2. US Diagnostic Biomarker Market by Application
5.2.1. Oncology
5.2.2. Cardiology
5.2.3. Neurology
5.2.4. Nephrology
5.2.5. Others
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.2. Acumen Pharmaceuticals, Inc.
6.3. Agilent Technologies, Inc.
6.4. Astute Medical, Inc.
6.5. Banyan Biomarkers, Inc.
6.6. Beckman Coulter Inc.
6.7. Becton, Dickson and Co.
6.8. Biodesix, Inc.
6.9. Bio-Rad Laboratories, Inc.
6.10. Critical Care Diagnostics, Inc.
6.11. Empire Genomics, LLC
6.12. Enzo Life Sciences, Inc.
6.13. Foundation Medicine, Inc.
6.14. Hologic, Inc.
6.15. Illumina, Inc.
6.16. Inova Diagnostics, Inc.
6.17. Luminex Corp.
6.18. Merck and Co., Inc.
6.19. Myriad Genetics, Inc.
6.20. NanoString Technologies, Inc.
6.21. NeoGenomics, Inc.
6.22. Pacific Biomarker Inc.
6.23. Pfizer, Inc.
6.24. Pliant Therapeutics, Inc.
6.25. Quest Diagnostics Inc.
6.26. Signosis Inc.
6.27. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Acumen Pharmaceuticals, Inc.
  • Agilent Technologies, Inc.
  • Astute Medical, Inc.
  • Banyan Biomarkers, Inc.
  • Beckman Coulter Inc.
  • Becton, Dickson and Co.
  • Biodesix, Inc.
  • Bio-Rad Laboratories, Inc.
  • Critical Care Diagnostics, Inc.
  • Empire Genomics, LLC
  • Enzo Life Sciences, Inc.
  • Foundation Medicine, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Inova Diagnostics, Inc.
  • Luminex Corp.
  • Merck and Co., Inc.
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • NeoGenomics, Inc.
  • Pacific Biomarker Inc.
  • Pfizer, Inc.
  • Pliant Therapeutics, Inc.
  • Quest Diagnostics Inc.
  • Signosis Inc.
  • Thermo Fisher Scientific Inc.